众生药业：昂拉地韦颗粒Ⅱ期临床试验完成首例参与者入组和给药

Core Viewpoint - The company, Zhongsheng Pharmaceutical, announced the completion of the first participant enrollment and dosing in the Phase II clinical trial of its innovative drug, ZSP1273 granules, for treating uncomplicated influenza A in patients aged 2 to 17 years [1] Group 1: Clinical Trial Progress - The Phase II clinical trial for ZSP1273 granules has successfully enrolled its first participant and commenced dosing [1] - The drug is specifically aimed at treating uncomplicated influenza A in children and adolescents aged 2 to 17 [1] Group 2: Preclinical Research Findings - Preclinical studies indicate that ZSP1273 demonstrates significantly superior inhibition of various influenza A viruses compared to neuraminidase inhibitors like Oseltamivir and endonuclease inhibitors such as Baloxavir [1] - ZSP1273 shows strong inhibitory effects against Oseltamivir-resistant strains, Baloxavir-resistant strains, and highly pathogenic avian influenza virus strains [1]